Marker Therapeutics Stock Performance
| MRKR Stock | USD 4.40 0.03 0.68% |
Marker Therapeutics has a performance score of 1 on a scale of 0 to 100. The company secures a Beta (Market Risk) of -0.0147, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Marker Therapeutics are expected to decrease at a much lower rate. During the bear market, Marker Therapeutics is likely to outperform the market. Marker Therapeutics right now secures a risk of 3.72%. Please verify Marker Therapeutics value at risk, as well as the relationship between the skewness and day median price , to decide if Marker Therapeutics will be following its current price movements.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Marker Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Even with relatively invariable forward-looking signals, Marker Therapeutics is not utilizing all of its potentials. The recent stock price agitation, may contribute to short-term losses for the retail investors. ...more
Actual Historical Performance (%)
One Day Return 2.04 | Five Day Return 5.63 | Year To Date Return (17.58) | Ten Year Return (98.68) | All Time Return (100.00) |
Last Split Factor 1:10 | Dividend Date 2016-09-16 | Last Split Date 2023-01-27 |
1 | Marker Therapeutics Ends Stock Sale Deal with LPC - TipRanks.com - TipRanks | 03/01/2024 |
2 | Acquisition by Baskett Forest of 5714285 shares of Marker Therapeutics at 1.75 subject to Rule 16b-3 | 03/08/2024 |
3 | Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors | 03/12/2024 |
4 | Acquisition by Hoang Peter L. of 430000 shares of Marker Therapeutics at 0.46 subject to Rule 16b-3 | 03/15/2024 |
5 | North American Morning Briefing Markets on Hold -2- - Morningstar | 03/20/2024 |
6 | Acquisition by Makhzoumi Mohamad of 5714285 shares of Marker Therapeutics at 1.75 subject to Rule 16b-3 | 03/22/2024 |
7 | Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results | 03/25/2024 |
8 | Is Marker Therapeutics In A Good Position To Invest In Growth - Yahoo Movies Canada | 04/11/2024 |
| Begin Period Cash Flow | 11.8 M |
Marker |
Marker Therapeutics Relative Risk vs. Return Landscape
If you would invest 439.00 in Marker Therapeutics on January 26, 2024 and sell it today you would earn a total of 1.00 from holding Marker Therapeutics or generate 0.23% return on investment over 90 days. Marker Therapeutics is currently generating 0.0723% in daily expected returns and assumes 3.7173% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Marker, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Marker Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Marker Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Marker Therapeutics, and traders can use it to determine the average amount a Marker Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0194
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | MRKR | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.72 actual daily | 32 68% of assets are more volatile |
Expected Return
| 0.07 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Marker Therapeutics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Marker Therapeutics by adding it to a well-diversified portfolio.
Marker Therapeutics Fundamentals Growth
Marker Stock prices reflect investors' perceptions of the future prospects and financial health of Marker Therapeutics, and Marker Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Marker Stock performance.
| Return On Equity | -0.83 | ||||
| Return On Asset | -0.35 | ||||
| Profit Margin | (2.49) % | ||||
| Operating Margin | (2.78) % | ||||
| Current Valuation | 22.19 M | ||||
| Shares Outstanding | 8.9 M | ||||
| Price To Earning | (9.39) X | ||||
| Price To Book | 2.73 X | ||||
| Price To Sales | 11.59 X | ||||
| Revenue | 3.31 M | ||||
| Gross Profit | (17.13 M) | ||||
| EBITDA | (14.58 M) | ||||
| Net Income | (14.05 M) | ||||
| Cash And Equivalents | 18.08 M | ||||
| Cash Per Share | 0.22 X | ||||
| Total Debt | 7.62 M | ||||
| Debt To Equity | 0.34 % | ||||
| Current Ratio | 1.99 X | ||||
| Book Value Per Share | 1.58 X | ||||
| Cash Flow From Operations | (16.44 M) | ||||
| Earnings Per Share | (1.59) X | ||||
| Market Capitalization | 39.4 M | ||||
| Total Asset | 17.13 M | ||||
| Retained Earnings | (436.29 M) | ||||
| Working Capital | 14.05 M | ||||
| Current Asset | 6.85 M | ||||
| Current Liabilities | 5.93 M | ||||
About Marker Therapeutics Performance
To evaluate Marker Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Marker Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Marker Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Marker Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Marker's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.000032 | 0.000033 | |
| Return On Tangible Assets | (0.99) | (1.04) | |
| Return On Capital Employed | (1.04) | (0.99) | |
| Return On Assets | (0.99) | (1.04) | |
| Return On Equity | (1.21) | (1.15) |
Things to note about Marker Therapeutics performance evaluation
Checking the ongoing alerts about Marker Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Marker Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Marker Therapeutics had very high historical volatility over the last 90 days | |
| Marker Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 3.31 M. Net Loss for the year was (14.05 M) with loss before overhead, payroll, taxes, and interest of (17.13 M). | |
| Marker Therapeutics currently holds about 18.08 M in cash with (16.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22. | |
| Marker Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 12.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Is Marker Therapeutics In A Good Position To Invest In Growth - Yahoo Movies Canada |
- Analyzing Marker Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Marker Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Marker Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Marker Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Marker Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Marker Therapeutics' stock. These opinions can provide insight into Marker Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Marker Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. To learn how to invest in Marker Stock, please use our How to Invest in Marker Therapeutics guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for Marker Stock analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
Is Marker Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Marker Therapeutics. If investors know Marker will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Marker Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.59) | Revenue Per Share 0.376 | Quarterly Revenue Growth 0.392 | Return On Assets (0.35) | Return On Equity (0.83) |
The market value of Marker Therapeutics is measured differently than its book value, which is the value of Marker that is recorded on the company's balance sheet. Investors also form their own opinion of Marker Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Marker Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Marker Therapeutics' market value can be influenced by many factors that don't directly affect Marker Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Marker Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Marker Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Marker Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.